A non-invasive, multi-target approach to treat diabetic retinopathy

Julius, Angeline; Hopper, Waheeta

doi:10.1016/j.biopha.2018.10.185

Cited by 30 publications

(14 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging of the retinal layers using the advanced techniques is challenging due to the non-availability of the sophisticated non-invasive system where the retinal size animal models is ten-fold smaller than that of humans. Also, there are very limited in vivo ocular non-invasive imaging methods available for retinopathy with in depth resolution [102][103][104][105][106][107]. Recently, an early detection of DR using a non-mydriatic, full field electroretinopathy, easy to operate devise was reported.…”

Section: Imaging Biomarkersmentioning

confidence: 99%

Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics

Sadasivam¹,

Gopinath²,

Shakya³

et al. 2021

Nanotheranostics

View full text Add to dashboard Cite

Diabetes Retinopathy (DR) is one of the most prominent microvascular complications of diabetes. It is one of the pre-eminent causes for vision impairment followed by blindness among the working-age population worldwide. The de facto cause for DR remains challenging, despite several efforts made to unveil the mechanism underlying the pathology of DR. There is quite less availability of the low cost pre-emptive theranostic imaging tools in terms of in-depth resolution, due to the multiple factors involved in the etiology of DR. This review work comprehensively explores the various reports and research works on all perspectives of diabetic retinopathy (DR), and its mechanism. It also discusses various advanced non-destructive imaging modalities, current, and future treatment approaches. Further, the application of various nanoparticle-based drug delivery strategies used for the treatment of DR are also discussed. In a nutshell, the present review work bolsters the pursuit of the development of an advanced non-invasive optical imaging modal with a nano-theranostic approach for the future diagnosis and treatment of DR and its associated ocular complications.

show abstract

Section: Imaging Biomarkersmentioning

confidence: 99%

Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics

Sadasivam¹,

Gopinath²,

Shakya³

et al. 2021

Nanotheranostics

View full text Add to dashboard Cite

show abstract

“…The most critical step in controlling DR is controlling the factors associated with the progression of DR. Since ALR2 inhibition could potentially control the factors associated, efficient inhibition of ALR2 by potent ARIs is necessary [ 21 ]. Initially, two classes of ARIs belonging to the class of spirosuccinimide and carboxylic acids were broadly in use.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Aldose Reductase by Novel Phytocompounds: A Heuristic Approach to Treating Diabetic Retinopathy

Julius

Renuka

Hopper

et al. 2022

Evidence-Based Complementary and Alternative Medicine

Self Cite

View full text Add to dashboard Cite

Aldose reductase (ALR2) activation in the polyol pathway has been implicated as the primary mechanism for the progression of diabetic retinopathy. Most of the aldose reductase inhibitors (ARIs), used for the treatment of diabetic complications, were withdrawn due to ineffective treatment and adverse side effects caused by nonspecificity. Epalrestat, a carboxylic acid inhibitor, is the only ARI used for the treatment of diabetic neuropathy, though associated with minor side effects to 8% of the treated population. Our study exploited the interactions of Epalrestat-ALR2 crystal structure for the identification of specific phytocompounds that could inhibit human lens ALR2. 3D structures of plant compounds possessing antidiabetic property were retrieved from PubChem database for inhibition analysis, against human lens ALR2. Among the shortlisted compounds, Agnuside and Eupalitin-3-O-galactoside inhibited lens ALR2 with IC50 values of 22.4 nM and 27.3 nM, respectively, compared to the drug Epalrestat (98 nM), indicating high potency of these compounds as ALR2 inhibitors. IC50 concentration of the identified ARIs was validated in vitro using ARPE-19 cells. The in silico and in vitro approaches employed to identify and validate specific and potent ALR2 inhibitors resulted in the identification of phytocompounds with potency equal to or better than the ALR2 inhibiting drug, Epalrestat.

show abstract

“…Diabetes is the major cause of blindness which mostly affects the working-age population [2]. Between 1996 to 2009 the prevalence of diabetes increased from 439,123 to 1,140,248 over 20 years [3]. Delhi based expert's clinical data states that the rise in the number of DR is among the people affected by diabetes.…”

Section: Introductionmentioning

confidence: 99%

Detection and Grading of Diabetic Retinopathy in Retinal Images Using Deep Intelligent Systems: A Comprehensive Review

H¹,

Anitha²,

Popescu³

et al. 2021

Computers, Materials &Amp; Continua

View full text Add to dashboard Cite

Diabetic Retinopathy (DR) is an eye disease that mainly affects people with diabetes. People affected by DR start losing their vision from an early stage even though the symptoms are identified only at the later stage. Once the vision is lost, it cannot be regained but can be prevented from causing any further damage. Early diagnosis of DR is required for preventing vision loss, for which a trained ophthalmologist is required. The clinical practice is time-consuming and is not much successful in identifying DR at early stages. Hence, Computer-Aided Diagnosis (CAD) system is a suitable alternative for screening and grading of DR for a larger population. This paper addresses the different stages in CAD system and the challenges in identifying and grading of DR by analyzing various recently evolved techniques. The performance metrics used to evaluate the Computer-Aided Diagnosis system for clinical practice is also discussed.

show abstract

A non-invasive, multi-target approach to treat diabetic retinopathy

Cited by 30 publications

References 76 publications

Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics

Non-invasive multimodal imaging of Diabetic Retinopathy: A survey on treatment methods and Nanotheranostics

Inhibition of Aldose Reductase by Novel Phytocompounds: A Heuristic Approach to Treating Diabetic Retinopathy

Detection and Grading of Diabetic Retinopathy in Retinal Images Using Deep Intelligent Systems: A Comprehensive Review

Contact Info

Product

Resources

About